Intuitive Surgical Devices in the news

Intuitive Surgical showed strong Q4 2025 results but gave cautious 2026 guidance, causing a stock dip despite its leading position in robotic surgery and long-term growth potential.

Intuitive Surgical's da Vinci system is the leading robotic platform for minimally invasive surgery, supported by a broad ecosystem and strong data integration, maintaining market dominance despite rising competition.

Robotic surgery is evolving with new competitors entering the market, expanding applications, and Intuitive Surgical innovating to maintain leadership amid growing competition.

FDA approved non-force feedback instruments for Intuitive Surgical's da Vinci 5 robot in cardiac surgeries, with ongoing development of force feedback tools and strong Q4 2025 financial performance.

Intuitive Surgical is expected to grow over the next five years with its da Vinci 5 system despite rising competition from Medtronic and Johnson & Johnson.

Intuitive Surgical grew its global robotic surgery platforms and procedures in 2025, introduced new platform features, and maintained strong market share despite some competitive challenges.

Intuitive Surgical's robotic surgery systems see strong demand and expanding FDA approvals, driving significant growth and a high stock valuation.

Generative AI is transforming the Medical Instruments industry, with regulatory adaptations and strong growth prospects despite supply chain and funding challenges, benefiting companies like Intuitive Surgical.

Intuitive Surgical is growing through advanced minimally invasive surgical systems amid industry-wide AI integration and M&A activity, despite sector challenges.

Intuitive Surgical transformed operating rooms with its da Vinci robotic systems, leading in minimally invasive surgery through advanced robotics, extensive clinical data, and a broad procedure ecosystem while facing increasing competition.

Intuitive Surgical’s focused robotic surgery platform offers higher growth and margin potential compared to Stryker’s diversified but steadier MedTech portfolio.

Intuitive Surgical improved female leadership and inclusive design through global mentorship, sponsorship, and authentic cultural connections.

Intuitive Surgical delivered a strong Q3 with 22.9% revenue growth and significant analyst beats, driving a 24.3% stock rise amid steady sector performance.

Intuitive Surgical led Q3 growth and earnings beats in the surgical equipment sector, while peers showed mixed results and guidance.

Intuitive Surgical led Q3 2025 growth in surgical equipment with strong revenue gains and stock performance despite industry challenges.

Intuitive Surgical expanded FDA clearance for its da Vinci SP system to new procedures but faced a stock downgrade amid rising competition and strong recent sales.

Intuitive Surgical led Q3 earnings in surgical equipment with strong revenue growth and stock gains, while peers showed mixed results.

Intuitive Surgical's growing use of AI in its da Vinci surgical robots and increasing procedure volumes suggest strong long-term growth potential and a possible 50% stock rise.

Intuitive Surgical's da Vinci robotic system sees growing demand and AI integration, driving strong procedure growth and potential stock gains.

Intuitive Surgical exceeded Q3 expectations with strong sales and growth in da Vinci systems, while competitors Medtronic and Johnson & Johnson advance their own surgical robots.